LBL-007 + tislelizumab + cisplatin

LBL-007 + tislelizumab + cisplatin is a combination therapy under clinical investigation, primarily for advanced and metastatic solid tumors (including nasopharyngeal carcinoma and other malignancies). - **LBL-007** is a monoclonal antibody targeting lymphocyte-activation gene 3 (LAG-3), acting as an immune checkpoint inhibitor to potentiate T cell activation and anti-tumor immune effects. - **Tislelizumab** is a humanized IgG4 monoclonal antibody targeting programmed death-1 (PD-1), inhibiting PD-1-mediated immune suppression and enhancing anti-tumor immunity. - **Cisplatin** is a cytotoxic small molecule platinum compound, causing DNA crosslinking, ultimately leading to apoptosis of rapidly dividing cells. The combination harnesses dual immune checkpoint blockade (LAG-3 and PD-1) with cytotoxic chemotherapy, aiming to synergize immune modulation with direct tumor cell killing. Clinical trials demonstrate encouraging efficacy, especially in immunotherapy-naive nasopharyngeal carcinoma, and have established recommended doses for future pivotal studies[5][7].

Brand names

tislelizumab (generic/brand, rarely sold under trade names)cisplatin (generic, trade names vary regionally)LBL-007 (code name)

Other names

anti-LAG-3 antibody LBL-007anti-LAG3 antibody LBL-007anti-LAG 3 antibody LBL-007anti-PD-1 antibody tislelizumabanti-PD1 antibody tislelizumabanti-PD 1 antibody tislelizumabplatinum agent cisplatin